Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies
Article 2025 en
Authors
AS
Adel Shahnam
NH
Nadia Hitchen
SM
Sathya Manoharan
Abstract
1 min read
Age alone was not associated with safety outcomes in phase 1 clinical trials for metastatic solid malignancies. Instead, comorbidity burden and ECOG performance status were predictors of adverse events in our cohort of patients.
Thierry Façon, Meletios A Dimopoulos, Nathalie Meuleman, Andrew Belch, Mohamad Mohty, Wen‐Ming Chen, Kihyun Kım, Elena Zamagni, Paula Rodríguez‐Otero, William Renwick, Christian Rosé, Adrian Tempescul, Eileen M. Boyle, Salomon Manier, Michel Attal, Philippe Moreau, Margaret Macro, Xavier Leleu, Marie Lorraine Chrétien, Heinz Ludwig, Shien Guo, Michael Sturniolo, Antoine Tinel, Mara Silvia Monzini, Bruno Costa, Vanessa Houck, Cyrille Hulin, Jean Yves Mary
Carmel Pezaro, Aurelius Omlin, Deborah Mukherji, Diletta Bianchini, Shahneen Sandhu, Amy Mulick, Gal Maier, David Olmos, Emilda Thompson, Gerhardt Attard, Johann S. de Bono
Sant P. Chawla, Garrett T. Wasp, Dale R. Shepard, Jean Yves Blay, Robin L. Jones, Silvia Stacchiotti, Peter Reichardt, Hans Gelderblom, Javier Martín‐Broto, Brendan P. Eckelman, Michelle Darling, Vasily Andrianov, Anthony P. Conley
Shinji Inaba, Gary S. Mintz, Naim Farhat, Jean Fajadet, Dariusz Dudek, Antonío Marzocchi, Barry Templin, Giora Weisz, Ke Xu, Bernard De Bruyne, Patrick W. Serruys, Gregg W. Stone, Akiko Maehara
Discussion(0)
No comments yet. Be the first to comment.